Sign up USA
Proactive Investors - Run By Investors For Investors

ImpediMed enrols first patient in chronic heart failure trial

The company is planning its European launch in calendar year 2017
Hospital
Heart failure currently costs the U.S. circa US$31bn per year

ImpediMed Ltd (ASX:IPD) has enrolled the first patient in its initial chronic heart failure (CHF) trial using the company’s “SOZO” device.

SOZO uses bioimpedance spectroscopy (BIS) technology to manage and monitor a person’s fluid status, body composition and hydration in a clinical or at-home setting.

This initial study will monitor up to 30 patients with chronic heart failure in a clinical setting for 30 days, and is expected to be completed in the calendar year 2017.

READ: ImpediMed begins lymphoedema study using its health device

If successful, SOZO is expected to provide an early warning system for cardiac decompensation with the potential to optimise patient care and significantly reduce hospital readmissions.

The real-world data generated will be used to form the basis for the design of a larger scale trial expected to be initiated by late 2017.

CHF is among the most expensive diseases in the U.S with an estimated 6.5 mln people suffering from heart failure, with more than 850,000 new patients diagnosed each year.

Heart failure currently costs the U.S. circa US$31bn per year, and is estimated to increase to US$70bn by 2030.

The company obtained CE (European Conformity) mark for SOZO in June 2017 and plans to initiate the European launch of SOZO in key commercial sites in calendar year 2017.

View full IPD profile View Profile

ImpediMed Timeline

Newswire
November 13 2013

Related Articles

Cholesterol gauge
July 25 2017
The assessment of Lojuxta, also known as lomitapide, followed the progress of patients with Homozygous Familial Hypercholesterolaemia
GW_Pharma.png
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use